Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for PT-141 (bremelanotide)

11 records for PT-141 (bremelanotide), of which 2 are published trials.

Showing 0 records on this page

Records

11 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
RECONNECT-301PT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled6262019Moderate
RECONNECT-302PT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled6302019Moderate
RECONNECT-301-BODY-COMPprogramme recordPT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled2019Very low
RECONNECT-302-DDIprogramme recordPT-141 (bremelanotide)Phase 1ReportedRandomised crossover2019Very low
RECONNECT-301-REGIONAL-JPprogramme recordPT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled2019Very low
RECONNECT-302-HEPATIC-IMPprogramme recordPT-141 (bremelanotide)Phase 1ReportedPhase 1 ascending dose2019Very low
RECONNECT-301-REGIONAL-CNprogramme recordPT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled2019Very low
RECONNECT-302-RENAL-IMPprogramme recordPT-141 (bremelanotide)Phase 1ReportedPhase 1 ascending dose2019Very low
RECONNECT-301-QOLprogramme recordPT-141 (bremelanotide)Phase 3ReportedRandomised, double-blind, placebo-controlled2019Very low
RECONNECT-302-PKprogramme recordPT-141 (bremelanotide)Phase 1ReportedPhase 1 ascending dose2019Very low
RECONNECT-301-ADHERENCEprogramme recordPT-141 (bremelanotide)Phase 3ReportedObservational2019Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.